Strategic Acquisition Evergen was recently acquired by RTI Surgical, creating a larger platform for collagen and biomaterials. This integration suggests expanded product lines, cross-sell opportunities to RTI Surgical customers, and potential access to broader distribution channels and sales resources.

Regenerative Focus The company specializes in medical grade collagen, tissues, and biomaterials for regenerative medicine across orthopedics, cardiovascular, dental, wound healing, neurology and urology. Opportunities exist to position expanded collagen scaffolds and tissue engineering solutions to adjacent medical device and biotech customers seeking regenerative solutions.

Growth Capabilities With a revenue range of $25M-$50M and a history of facility expansion in Glasgow to meet rising demand, there is demonstrated capacity for scaling production. This supports pursuing larger multi-year contracts with hospital systems, academic centers, and device manufacturers.

Funding & Innovation Past grants and funding rounds indicate ongoing R&D activity and potential for collaborations on new biomaterials, scaffolds, or device integrations. Sales opportunities may arise from co-development partnerships, government-funded programs, and early-stage trials with research institutions.

Partnered Growth As a former Collagen Solutions and current RTI Surgical portfolio member, there is potential to leverage RTI’s existing customer base, channels, and strategic relationships to accelerate adoption of Evergen’s products, while also identifying complementary product bundles for medical devices and regenerative therapies.